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SUMMARY
Diabetes mellitus is associated with high
morbidity and mortality. The high cost of
treatment is a major concern to both physicians
and patients. This study assessed pattern and cost
of drugs prescribed at a diabetic clinic, and
identified the commonest reasons militating
against adherence to therapy.The study was a
cross-sectional survey. Data was obtained from
all prescriptions issued following each day’s
consultation. Patients were also interviewed
using a self-administered questionnaire. Means
were compared using t-test and chi2 was used to
test associations. P-value < 0.05 was considered
significant statistically. Three hundred and forty-
nine (349) diabetic patients were seen. There were
more females than males (61.9% & 38.1%).
About 36% (125) of the patients had no formal
education and 12% (42) had only primary
education, while 80% were from the low socio-
economic class. The average number of drugs
prescribed/day was 4 with an average cost of
medications/day being N183.5 ±150.4 (Nigerian
naira) approx $1.40 (USD). The commonest
reasons that militate against adherence to
prescribed drugs were the high cost of the drugs
(52.2%) and the large number of drugs to be
taken (43.5%). Biguanides (66%) are the
commonest oral hypoglycemic agents prescribed,
while ACEIs (53%) were the commonest
antihypertensive prescribed. Only 5.4% of
patients received statins. The cost of medications
prescribed to diabetic patients in Ibadan, Nigeria
is quite high. Every effort at cost reduction
through improved prescription of drugs as
generics and rational prescribing is necessary so
as to encourage adherence to drug therapy.
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INTRODUCTION
Diabetes mellitus is a major non-communicable
disease with a higher incidence in the developed
countries[1]. However, there is demonstrable
evidence to show that the incidence is rising in
developing countries with prevalence estimates in
Africa of 1% in rural areas and 5-7% in urban sub-
Saharan Africa, while estimates of up to 13% has
been reported in more developed areas in South
Africa and Indian populations[2, 3, 4, 5]. The burden
of diabetes mellitus in Nigeria is similar to what has
been observed in other parts of sub-Saharan Africa.
The prevalence of diabetes mellitus varies between
1% and 8% depending on the area of the country
that is surveyed[6, 7, 8, 9].
While recognizing the need to treat diabetes
mellitus in a developing country like Nigeria using
drugs with proven efficacy based on best evidence,
the prevailing social, cultural and economic
environment of individual patients must be
considered. Most patients with diabetes in Nigeria
have little or no formal education and are poor with
little understanding of the nature of their disease[10,
11]. Additionally, scarcity of health resources,
prohibitive cost of drugs or their non-availability, sale
of fake drugs and the easy access to the traditional
and faith healers militate against the optimal
management of a chronic disease like diabetes
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mellitus[12]. The care of diabetes is expensive com-
pared to management of other chronic illnesses. In
the United States, the per capita annual costs of health
care for people with diabetes rose from $10,071 in
1997 to $13,243 in 2002, an increase of more than
30%, while health care costs for people without dia-
betes amounted to $2,560 in 2002; with the total
annual economic cost of diabetes in 2002 estimated
to be $132 billion[13]. A direct cost estimate of the
treatment of diabetes in Nigeria is necessary in the
context of the large indigent diabetic population.
Provision of drugs in their generic names and ratio-
nal prescription of drugs are recognized measures
that can considerably reduce cost of drugs to pa-
tients without a fall in treatment standards towards
attaining optimal diabetic control.
This study aims at assessing the pattern of drug
prescription using some World Health Organization
(WHO) drug use indicators, including the daily cost
of medications to patients as well as identifying the
commonest reasons militating against adherence to
drugs therapy.
MATERIALS AND METHODS
The study was carried out at the Medical Outpatient
Clinic (MOP) of the University College Hospital (a
850-bed tertiary care hospital), Ibadan, Nigeria.
Ibadan is the largest indigenous town in Africa, south
of the Sahara and it is located in south-western
Nigeria, 125 kilometers from Lagos. It has a
calculated population of 3,800,000, while the
Yoruba comprise its principal inhabitants.
Ethical approval for the study was obtained
from the University of Ibadan/University College
Hospital Joint Institution Review Committee (UI/
UCH JIRC).
Seven specialty clinics in internal medicine are
run in the MOP weekly including endocrinology
where most patients with diabetes mellitus are seen
in addition to other medical conditions including
thyrotoxicosis, hypertension, etc.
The study was part of  a larger cross-sectional
survey over an eight (8) working week period
between December 2004 and February 2005. The
endocrinology clinic is held once a week on Monday
mornings. All prescriptions issued to patients
attending the endocrinology clinic during this period
immediately following each day’s consultation at the
MOP were copied out from the case files and
recorded on specially designed case record forms.
Prescriptions obtained were used to characterize the
prescribing patterns at the clinics by applying some
WHO Drug Use Indicators[14]. WHO drug use
indicators assessed were the average number of
drugs prescribed per encounter, percentage of drugs
prescribed by generic name, percentage of drugs
prescribed from hospital essential drug list and
formulary and average cost of drugs per encounter.
The percentage of drugs prescribed from the hospital
essential drug list was determined using the third
edition of the hospital Essential Drug List and
Formulary (2003)[15]. A pharmacist in the hospital
pharmacy using the current hospital drug-pricing list
calculated the cost of the prescribed drugs.
Prescriptions of patients with serious medical
conditions requiring subsequent hospital admission
were excluded. Intravenous fluids and blood
transfusions were also not regarded as prescribed
drugs for the purpose of this study. All improperly
or incompletely written prescriptions were noted but
excluded from the final analysis.
Patients to be seen at the MOP during the
study period were interviewed just before
consultation commenced to assess the commonest
reasons for non-adherence to medical therapy using
a self-administered questionnaire or investigator
assisted in the case of illiterate patients.
According to the World Health Organization
document on ‘How to investigate drug use in Health
facilities’ (1993), a minimum of 100 prescriptions
per clinic is expected to give a 95% confidence
interval of within 10% for the individual result[16].
All data were entered into SPSS 10.0 for windows.
In the statistical analysis, frequencies, mean values
and percentages were presented. Comparison of
means was done using t-test and chi square used to
compare variables. A P  value < 0.05 was
considered statistically significant.
RESULTS
A total of 354 patients were seen at the
endocrinology clinic during the study period. Three
hundred and forty nine (98.6%) of the patients had
diabetes mellitus with or without hypertension, while
3 (0.8%) had thyrotoxicosis and 2 (0.6%) had
pulmonary tuberculosis. Only prescriptions of those
with diabetes mellitus were included in the analysis.
Three hundred and twenty three (92.6%) of the
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patients were seen on follow-up basis while only
twenty six (7.4%) of the patients were new cases.
Females with diabetes mellitus were 216 (61.9%)
while the males were 133 (38.1%). Both sexes were
similarly matched for age (Average age of 57.8yrs
±12 for females with a range of 21-81yrs; and
57.2yrs ±15 for males with a range of 16-82yrs;
P  = 0.67, 95%CI -3.4, 2.2). Table 1 shows details
of level of education and occupational distribution
of patients.
Analysis of the prescription pattern using some
World Health Organization (WHO) core drug use
indicators shows that the average number of drugs
prescribed/day at the diabetic clinic is 4; percentage
of drugs prescribed in their generic name is 47.5%
±27.6; percentage of drugs prescribed from the
hospital essential drug list (EDL) is 98.6% ±5.6; and
the mean and median daily cost of medications to
the patients are  N183.5 ±150.4 and  N 156
(Nigerian Naira), approx $1.42 and $1.2 (USD)
respectively.
However, 35% of female patients were
prescribed less than 4 drugs as compared to 28%
of their male counterparts (ñ= 0.147; OR 1.4;
95%CI 0.9, 2.3) despite the fact that 52% of both
sexes had only diabetes mellitus as a single diagno-
sis (P = 0.94; OR 0.98; 95%CI 0.6, 1.5).
Two hundred and twenty five (225) patients
consented to answer the study questionnaire. The
commonest complaint and reason for non-adherence
to therapy given by the follow-up patients is the high
cost of the drugs (52.2%). While 43.5% thought
that the large number of drugs to be taken
discourages adherence to therapy; only 13% of
follow-up patients attributed non-adherence to
therapy to the side effects of the drugs.
Table 2 shows the percentage of diabetic
patients prescribed various drugs during the study
period. Biguanides (65.9%) were the most often
prescribed hypoglycemic agents while 26.4% of
patients received insulin. Angiotensin Converting
Enzyme Inhibitors or Angiotensin Receptor Blockers
(ACEI/ARBs) (52.7%) were the most often
prescribed antihypertensive drugs in patients who
also had high blood pressure. Antiplatelets (Aspirin
75-150mg) were prescribed to 56.4% of the patients
while only 5.4% of patients had statins prescribed.
DISCUSSION
Diabetes mellitus is a potentially devastating disease
associated with increased morbidity and mortality.
Many studies have demonstrated the need to
TABLE 2: Percentage distribution of patients presc-
ribed various drugs at the diabetic clinic
Drug  types        Number of
   patients
(N= 349)
     (%)
Antidiabetics Biguanides 230 (65.9%)
agents Sulphonylureas 189 (54.2%)
Insulin 92 (26.4%)
Antihypertensives ACEI/ARBs 184 (52.7%)
Calcium
antagonists 128 (36.7%)
Alpha methyldopa 36 (10.3%)
Diuretics 24 (6.9%)
â-blockers 5 (1.4%)
Others Antiplatelets 197 (56.4%)
Statins 19 (5.4%)
TABLE 1: Educational and occupational distribution
of patients seen at the diabetic clinic
Demographic        Number of patients
characteristics               (%)





Occupation Petty traders 195 (56%)





Civil servants 14 (4%)
Unemployed 14 (4%)
Total 349 (100%)
Drug Prescription and Cost in Diabetes
The role of ACE inhibitors in the reduction of car-
diovascular associated morbidity and mortality
is established [22]. The human insulin, ACEIs and
statins are expensive, many of which still exist in their
brand names. However, use of ACE inhibitors and
statins preferably in their cheaper generic forms
where available should be prescribed for all diabetes
patients. Perhaps introduction of “polypills” will also
reduce the cost and number of drugs while
maintaining treatment goals. The polypill is a type of
drug that would contain medications to lower
cholesterol and blood pressure, aspirin as anticlotting
agent, and folic acid to help prevent atherosclerosis
all combined in a tablet.
Calcium antagonists are used more often in
Ibadan compared to Sagamu where alpha-blockers
and centrally acting drugs are the commonly
prescribed antihypertensive drug.
The lipid lowering agents (statins) were
prescribed only to a small proportion of patients.
Evidence now exists about the benefit of statins in
reducing cardiovascular events in diabetic patients
independent of lipid levels [23, 24]. However, the
high cost of these drugs may limit their prescription
in our diabetic population where the emphasis is on
adequate blood pressure and blood glucose control.
CONCLUSION
This study shows that most patients attending the
diabetic clinic in UCH Ibadan are mainly from the
low socio-economic class. The cost of daily
medications to patients is expectedly high due to the
high number of drugs prescribed and the low
percentage of drugs prescribed in their generic
names. The cost of drugs is the commonest reason
given by patients militating against adherence to
therapy. The prescription of ACEIs is commendable
but can be improved.
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